Study S001000

A Multicentre, Prospective, Non-interventional Single-arm Study Investigating Clinical Parameters Associated With the Initiation of Once-daily Oral Semaglutide in a Real-world Adult Population With Type 2 Diabetes in India

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05502562
Acronym: PIONEER REAL
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 388
Start: 2023-02-24
Primary completion: 2024-06-03
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Oral semaglutide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1270-0826

Registered primary outcomes

Change in Glycated haemoglobin A1c (HbA1c) [From baseline (week 0) to End of Study visit (V3) (week 34-44)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0017712	Real-World Usage of Once-Daily Oral Semaglutide in Adults with Type 2 Diabetes: Findings from PIONEER REAL India. Sanyal D, Indian journal of endocrinology and metabolism	2025	Nonrandomized study	PMID 41229720 DOI	cites ClinicalTrials.gov:NCT05502562; registry reference DERIVED:41229720